Robert A. Brodsky, MD, Begins Term as 2023 ASH President
(WASHINGTON, Jan. 10, 2023) — Robert A. Brodsky, MD, a renowned expert in classical hematology, will serve as president of the American Society of Hematology (ASH) for a year-long term through December 2023.
Dr. Brodsky is a Professor of Medicine and Oncology and Director of Hematology at Johns Hopkins University School of Medicine in Baltimore. His research interests include bone marrow failure states, a condition that occurs when the spongy tissue of the bone does not produce enough new blood cells, as well as bone marrow transplantation for non-malignant blood and complement system related disorders such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and antiphospholipid antibody syndrome.
“Groundbreaking advances in gene and cell therapies make this an incredibly exciting time to be in hematology,” said Dr. Brodsky. “As ASH President, I look forward to working with the talented and dedicated members of ASH to continue pushing the boundaries of what is possible in the treatment of these complex and often devastating blood disorders.”
In addition to advancing hematology research and practice, Dr. Brodsky is also deeply dedicated to strengthening the hematology work force and played a pivotal role in the launch of ASH’s Hematology Focused Fellowship Training Program (HFFTP). Through HFFTP, ASH invested $19 million into the development of hematology-specific fellowship programs at academic medical centers across the country, in pursuit of training 50 new academic hematologists by 2030.
“While hematology and oncology will always have a synergy between them, there remains an ever-growing need for classically trained hematologists to treat patients with non-malignant blood disorders,” said Dr. Brodsky. “Together, through HFFTP and other ASH-sponsored initiatives, we will continue to build the hematology workforce and advance the society’s mission to promote research, high-quality equitable clinical care, education, training, and advocacy in hematology.”
Dr. Brodsky has been a member of ASH for 30 years, and during that time he has served in various leadership roles representing the Society, most recently serving as ASH Secretary, and as Chair of the Scientific Committee on Bone Marrow Failure. Dr. Brodsky also previously served on the Editorial Board of Blood, ASH’s flagship journal, as well as serving on several ASH taskforces throughout his time with the Society.
The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. ASH’s flagship journal, Blood (www.bloodjournal.org), is the most cited peer-reviewed publication in the field, and Blood Advances (www.bloodadvances.org) is the Society’s online, peer-reviewed open-access journal.
Kira Sampson, American Society of Hematology
[email protected]; 202-499-1796